Euan A Ashley

List of Publications by Year
in descending order

232 papers	19,100 citations	16437 64 h-index	14736 127 g-index
252 all docs	252 docs citations	252 times ranked	28311 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19. Clinical Infectious Diseases, 2022, 74, 218-226.	2.9	51
2	The genetics of human performance. Nature Reviews Genetics, 2022, 23, 40-54.	7.7	25
3	Disruption of protein quality control of the human ether-Ã-go-go related gene K+ channel results in profound long QT syndrome. Heart Rhythm, 2022, 19, 281-292.	0.3	7
4	Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting. New England Journal of Medicine, 2022, 386, 700-702.	13.9	116
5	Causative Variants for Inherited Cardiac Conditions in a Southeast Asian Population Cohort. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003536.	1.6	1
6	Ultra-Rapid Nanopore Whole Genome Genetic Diagnosis of Dilated Cardiomyopathy in an Adolescent With Cardiogenic Shock. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003591.	1.6	3
7	A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Medicine, 2022, 14, 23.	3.6	101
8	High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiology, 2022, 7, 386.	3.0	63
9	Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatology Communications, 2022, 6, 1516-1526.	2.0	7
10	A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States. Nature Genetics, 2022, 54, 219-222.	9.4	14
11	Accelerated identification of disease-causing variants with ultra-rapid nanopore genome sequencing. Nature Biotechnology, 2022, 40, 1035-1041.	9.4	45
12	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	0.5	24
13	Single-nucleus chromatin accessibility profiling highlights regulatory mechanisms of coronary artery disease risk. Nature Genetics, 2022, 54, 804-816.	9.4	51
14	Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophy. European Heart Journal Digital Health, 2022, 3, 380-389.	0.7	10
15	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	1.4	6
16	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. Genetics in Medicine, 2021, 23, 69-79.	1.1	39
17	Graphical analysis for phenome-wide causal discovery in genotyped population-scale biobanks. Nature Communications, 2021, 12, 350.	5.8	13
18	Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases. Genetics in Medicine, 2021, 23, 1075-1085.	1.1	16

#	Article	IF	Citations
19	Whole-Transcriptome Profiling of Human Heart Tissues Reveals the Potential Novel Players and Regulatory Networks in Different Cardiomyopathy Subtypes of Heart Failure. Circulation Genomic and Precision Medicine, 2021, 14, e003142.	1.6	7
20	Cardiopulmonary Exercise Testing With Echocardiography to Assess Recovery in Patients With Ventricular Assist Devices. ASAIO Journal, 2021, Publish Ahead of Print, 1134-1138.	0.9	2
21	Benchmarking workflows to assess performance and suitability of germline variant calling pipelines in clinical diagnostic assays. BMC Bioinformatics, 2021, 22, 85.	1.2	12
22	Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e019944.	1.6	9
23	Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction. Circulation Genomic and Precision Medicine, 2021, 14, e003304.	1.6	73
24	Detection of a mosaic CDKL5 deletion and inversion by optical genome mapping ends an exhaustive diagnostic odyssey. Molecular Genetics & Genomic Medicine, 2021, 9, e1665.	0.6	11
25	Generation of three induced pluripotent stem cell lines, SCVIi003-A, SCVIi004-A, SCVIi005-A, from patients with ARVD/C caused by heterozygous mutations in the PKP2 gene. Stem Cell Research, 2021, 53, 102284.	0.3	4
26	Mulibrey Nanism and the Real Time Use of Genome and Biobank Engines to Inform Clinical Care in an Ultrarare Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003430.	1.6	0
27	Time trajectories in the transcriptomic response to exercise - a meta-analysis. Nature Communications, 2021, 12, 3471.	5.8	48
28	Towards precision medicine in heart failure. Nature Reviews Cardiology, 2021, 18, 745-762.	6.1	34
29	Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. Journal of Experimental Medicine, 2021, 218, .	4.2	139
30	Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries. American Journal of Cardiology, 2021, 148, 157-164.	0.7	48
31	Smartphone-Based VO2max Measurement With Heart Snapshot in Clinical and Real-world Settings With a Diverse Population: Validation Study. JMIR MHealth and UHealth, 2021, 9, e26006.	1.8	9
32	Combining Clinical and Polygenic Risk Improves Stroke Prediction Among Individuals With Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, e003168.	1.6	24
33	Combining digital data and artificial intelligence for cardiovascular health. Cardiovascular Research, 2021, 117, e116-e117.	1.8	2
34	Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2021, 148, 585-598.	1.5	20
35	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
36	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	1.0	43

#	Article	IF	Citations
37	Comparison of the FRIEND and Wassermanâ€Hansen Equations in Predicting Outcomes in Heart Failure. Journal of the American Heart Association, 2021, 10, e021246.	1.6	7
38	Deep learning evaluation of biomarkers from echocardiogram videos. EBioMedicine, 2021, 73, 103613.	2.7	25
39	Designing clinically translatable artificial intelligence systems for high-dimensional medical imaging. Nature Machine Intelligence, 2021, 3, 929-935.	8.3	29
40	Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms. Circulation Genomic and Precision Medicine, 2021, 14, CIRCGEN121003419.	1.6	8
41	Abstract 12101: Clinical Implications of Integrating Polygenic Risk Into Established Cardiovascular Disease Risk Scores. Circulation, 2021, 144, .	1.6	0
42	Echocardiographic Assessment of Left Ventricular Remodeling in American Style Footballers. International Journal of Sports Medicine, 2020, 41, 27-35.	0.8	1
43	Limitations of Electrocardiography for Detecting Left Ventricular Hypertrophy or Concentric Remodeling in Athletes. American Journal of Medicine, 2020, 133, 123-132.e8.	0.6	8
44	Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. Circulation, 2020, 142, 1605-1608.	1.6	33
45	Impact of the distance from the chest wall to the heart on surface ECG voltage in athletes. BMJ Open Sport and Exercise Medicine, 2020, 6, e000696.	1.4	3
46	Multi-task deep learning for cardiac rhythm detection in wearable devices. Npj Digital Medicine, 2020, 3, 116.	5.7	58
47	Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	1.6	47
48	Clinical utility of genomic sequencing: a measurement toolkit. Npj Genomic Medicine, 2020, 5, 56.	1.7	37
49	Digital Health Applications for Pharmacogenetic Clinical Trials. Genes, 2020, 11, 1261.	1.0	6
50	Molecular Choreography of Acute Exercise. Cell, 2020, 181, 1112-1130.e16.	13.5	261
51	The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. Genome Medicine, 2020, 12, 48.	3.6	40
52	Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiological Genomics, 2020, 52, 293-303.	1.0	29
53	Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy. Frontiers in Physiology, 2020, 11, 181.	1.3	18
54	Video-based AI for beat-to-beat assessment of cardiac function. Nature, 2020, 580, 252-256.	13.7	393

#	Article	IF	Citations
55	Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation. JAMA Network Open, 2020, 3, e202064.	2.8	62
56	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	1.6	70
57	Molecular Transducers of Physical Activity Consortium (MoTrPAC): Mapping the Dynamic Responses to Exercise. Cell, 2020, 181, 1464-1474.	13.5	147
58	Deep learning interpretation of echocardiograms. Npj Digital Medicine, 2020, 3, 10.	5.7	233
59	Classifying Drugs by their Arrhythmogenic Risk Using Machine Learning. Biophysical Journal, 2020, 118, 1165-1176.	0.2	23
60	Cardiac Imaging of Aortic Valve Area From 34 287 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic Comorbidity With Multiple Disease Phenotypes. Circulation Genomic and Precision Medicine, 2020, 13, e003014.	1.6	16
61	Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation. JCI Insight, 2020, 5, .	2.3	15
62	Time based versus strain based myocardial performance indices in hypertrophic cardiomyopathy, the merging role of left atrial strain. European Heart Journal Cardiovascular Imaging, 2019, 20, 334-342.	0.5	12
63	Personalized prediction of adverse heart and kidney events using baseline and longitudinal data from SPRINT and ACCORD. PLoS ONE, 2019, 14, e0219728.	1.1	4
64	Approaching Higher Dimension Imaging Data Using Cluster-Based Hierarchical Modeling in Patients with Heart Failure Preserved Ejection Fraction. Scientific Reports, 2019, 9, 10431.	1.6	5
65	Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation, 2019, 140, 765-778.	1.6	26
66	Weakly supervised classification of aortic valve malformations using unlabeled cardiac MRI sequences. Nature Communications, 2019, 10, 3111.	5.8	65
67	The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study. The Lancet Digital Health, 2019, 1, e344-e352.	5.9	52
68	Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. Journal of Genetic Counseling, 2019, 28, 1107-1118.	0.9	42
69	A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification apPLications In heart Failure studY (AMPLIFY). Npj Digital Medicine, 2019, 2, 80.	5.7	14
70	Cardiopulmonary Exercise Testing, Impedance Cardiography, and Reclassification of Risk in Patients Referred for Heart Failure Evaluation. Journal of Cardiac Failure, 2019, 25, 961-968.	0.7	11
71	Pathological Overlap of Arrhythmogenic Right Ventricular Cardiomyopathy and Cardiac Sarcoidosis. Circulation Genomic and Precision Medicine, 2019, 12, 452-454.	1.6	1
72	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Medicine, 2019, 11, 5.	3.6	90

#	Article	IF	Citations
73	Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PLoS ONE, 2019, 14, e0217612.	1.1	10
74	Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. Nature Communications, 2019, 10, 2760.	5.8	22
75	Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nature Medicine, 2019, 25, 911-919.	15.2	221
76	Targeted Long-Read RNA Sequencing Demonstrates Transcriptional Diversity Driven by Splice-Site Variation in MYBPC3. Circulation Genomic and Precision Medicine, 2019, 12, e002464.	1.6	12
77	Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation. American Journal of Cardiology, 2019, 123, 1822-1827.	0.7	24
78	A Patient with Sjogrenâ€™s Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis. Journal of General Internal Medicine, 2019, 34, 1058-1062.	1.3	6
79	Rapid Genome Sequencing in the Critically Ill. Clinical Chemistry, 2019, 65, 723-726.	1.5	6
80	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	1.6	96
81	Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. Scientific Data, 2019, 6, 24.	2.4	43
82	A toolkit for genetics providers in followâ€up of patients with nonâ€diagnostic exome sequencing. Journal of Genetic Counseling, 2019, 28, 213-228.	0.9	11
83	Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS ONE, 2019, 14, e0214250.	1.1	59
84	Loss of function, missense, and intronic variants in NOTCH1 confer different risks for left ventricular outflow tract obstructive heart defects in two European cohorts. Genetic Epidemiology, 2019, 43, 215-226.	0.6	25
85	A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. Circulation, 2019, 139, 799-811.	1.6	91
86	Athletic Remodeling in Female College Athletes: The â€œMorganroth Hypothesisâ€•Revisited. Clinical Journal of Sport Medicine, 2019, 29, 224-231.	0.9	20
87	A reference equation for maximal aerobic power for treadmill and cycle ergometer exercise testing: Analysis from the FRIEND registry. European Journal of Preventive Cardiology, 2018, 25, 742-750.	0.8	58
88	Applying current normative data to prognosis in heart failure: The Fitness Registry and the Importance of Exercise National Database (FRIEND). International Journal of Cardiology, 2018, 263, 75-79.	0.8	14
89	Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder. American Journal of Human Genetics, 2018, 102, 494-504.	2.6	59
90	Large Q and S waves in lead III on the electrocardiogram distinguish patients with hypertrophic cardiomyopathy from athletes. Heart, 2018, 104, 1871-1877.	1.2	5

#	Article	IF	Citations
91	Biological Insights Into Muscular Strength: Genetic Findings in the UK Biobank. Scientific Reports, 2018, 8, 6451.	1.6	78
92	Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. Nature Communications, 2018, 9, 1612.	5.8	95
93	Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 782-792.	1.6	72
94	A New Approach to Rare Diseases of Children: The Undiagnosed Diseases Network. Journal of Pediatrics, 2018, 196, 291-297.e2.	0.9	15
95	Right Ventricular Structure and Function in the Veteran Ultramarathon Runner: Is There Evidence for Chronic Maladaptation?. Journal of the American Society of Echocardiography, 2018, 31, 598-605.e1.	1.2	5
96	Long-read genome sequencing identifies causal structural variation in a Mendelian disease. Genetics in Medicine, 2018, 20, 159-163.	1.1	189
97	Incremental value of right heart metrics and exercise performance to well-validated risk scores in dilated cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2018, 19, 916-925.	0.5	6
98	Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. New England Journal of Medicine, 2018, 379, 2131-2139.	13.9	261
99	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e005191.	1.6	46
100	Telomere shortening is a hallmark of genetic cardiomyopathies. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9276-9281.	3.3	51
101	Cardiovascular Precision Medicine in the Genomics Era. JACC Basic To Translational Science, 2018, 3, 313-326.	1.9	52
102	Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H348-H356.	1.5	28
103	Genome Sequencing in HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 430-433.	1.2	5
104	Acetaminophen or Tylenol? A Retrospective Analysis of Medication Digital Communication Practices. Journal of General Internal Medicine, 2018, 33, 1218-1220.	1.3	5
105	Artificial Intelligence in Cardiology. Journal of the American College of Cardiology, 2018, 71, 2668-2679.	1.2	690
106	Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 2691-2701.	1.2	94
107	Genetic Reduction in Left Ventricular Protein Kinase C-Î± and Adverse Ventricular Remodeling in Human Subjects. Circulation Genomic and Precision Medicine, 2018, 11, e001901.	1.6	10
108	Cardiovascular disease: The rise of the genetic risk score. PLoS Medicine, 2018, 15, e1002546.	3.9	138

#	Article	IF	Citations
109	Effect of lossy compression of quality scores on variant calling. Briefings in Bioinformatics, 2017, 18, bbw011.	3.2	50
110	Next-Generation Sequencing in Cardiovascular Disease. Circulation, 2017, 135, 406-409.	1.6	33
111	The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease. American Journal of Human Genetics, 2017, 100, 185-192.	2.6	142
112	Orexin: a Missing Link Between Sleep Disorders and Heart Failure?. Current Heart Failure Reports, 2017, 14, 100-105.	1.3	8
113	Informed Consent. New England Journal of Medicine, 2017, 376, 856-867.	13.9	158
114	Left atrial function and phenotypes in asymmetric hypertrophic cardiomyopathy. Echocardiography, 2017, 34, 843-850.	0.3	9
115	Delivering Clinical Grade Sequencing and Genetic Test Interpretation for Cardiovascular Medicine. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	11
116	MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome. American Journal of Human Genetics, 2017, 100, 843-853.	2.6	181
117	A Reference Equation for Normal Standards for VO 2 Max: Analysis from the Fitness Registry and the Importance of Exercise National Database (FRIEND Registry). Progress in Cardiovascular Diseases, 2017, 60, 21-29.	1.6	136
118	Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2017, 317, 1349.	3.8	160
119	Feasibility of Obtaining Measures of Lifestyle From a Smartphone App. JAMA Cardiology, 2017, 2, 67.	3.0	207
120	Load-dependent effects of apelin on murine cardiomyocytes. Progress in Biophysics and Molecular Biology, 2017, 130, 333-343.	1.4	36
121	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	42
122	Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.	0.8	19
123	Contractile reserve and cardiopulmonary exercise parameters in patients with dilated cardiomyopathy, the two dimensions of exercise testing. Echocardiography, 2017, 34, 1179-1186.	0.3	8
124	Value of Strain Imaging and Maximal Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 120, 1203-1208.	0.7	10
125	Navigating Genetic and Phenotypic Uncertainty in Left Ventricular Noncompaction. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	7
126	Accuracy in Wrist-Worn, Sensor-Based Measurements of Heart Rate and Energy Expenditure in a Diverse Cohort. Journal of Personalized Medicine, 2017, 7, 3.	1.1	420

#	Article	IF	Citations
127	Impact of a Genetic Risk Score for Coronary Artery Disease on Reducing Cardiovascular Risk: A Pilot Randomized Controlled Study. Frontiers in Cardiovascular Medicine, 2017, 4, 53.	1.1	44
128	Deep Learning Automates the Quantitative Analysis of Individual Cells in Live-Cell Imaging Experiments. PLoS Computational Biology, 2016, 12, e1005177.	1.5	429
129	Alterations in Cardiac Mechanics Following Ultra-Endurance Exercise: Insights from Left and Right Ventricular Area-Deformation Loops. Journal of the American Society of Echocardiography, 2016, 29, 879-887.e1.	1.2	26
130	Denoising of Quality Scores for Boosted Inference and Reduced Storage. , 2016, 2016, 251-260.		2
131	Exploratory insights from the rightâ€sided electrocardiogram following prolonged endurance exercise. European Journal of Sport Science, 2016, 16, 1014-1022.	1.4	10
132	Comparison of left ventricular manual versus automated derived longitudinal strain: implications for clinical practice and research. International Journal of Cardiovascular Imaging, 2016, 32, 429-437.	0.7	25
133	Medical implications of technical accuracy in genome sequencing. Genome Medicine, 2016, 8, 24.	3.6	123
134	The Undiagnosed Diseases Programâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 315, 1904.	3.8	0
135	In Vivo Postâ€"Cardiac Arrest Myocardial Dysfunction Is Supported by Ca ²⁺ /Calmodulin-Dependent Protein Kinase Iiâ€"Mediated Calcium Long-Term Potentiation and Mitigated by Alda-1, an Agonist of Aldehyde Dehydrogenase Type 2. Circulation, 2016, 134, 961-977.	1.6	17
136	Early somatic mosaicism is a rare cause of long-QT syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11555-11560.	3.3	39
137	Functional assessment and transplantation of the donor heart after circulatory death. Journal of Heart and Lung Transplantation, 2016, 35, 1443-1452.	0.3	187
138	Towards precision medicine. Nature Reviews Genetics, 2016, 17, 507-522.	7.7	651
139	Taming the genome: towards better genetic test interpretation. Genome Medicine, 2016, 8, 70.	3.6	5
140	A research roadmap for next-generation sequencing informatics. Science Translational Medicine, 2016, 8, 335ps10.	5.8	37
141	Multidimensional structure-function relationships in human Î²-cardiac myosin from population-scale genetic variation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6701-6706.	3.3	98
142	Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy. Echocardiography, 2016, 33, 686-694.	0.3	22
143	Hypertrophic Cardiomyopathy as a Cause ofÂSudden Cardiac Death in the Young: A Meta-Analysis. American Journal of Medicine, 2016, 129, 486-496.e2.	0.6	57
144	Athlome Project Consortium: a concerted effort to discover genomic and other â€œomicâ€•markers of athletic performance. Physiological Genomics, 2016, 48, 183-190.	1.0	96

#	Article	IF	Citations
145	Sports genetics moving forward: lessons learned from medical research. Physiological Genomics, 2016, 48, 175-182.	1.0	26
146	Redox regulation of vascular remodeling. Cellular and Molecular Life Sciences, 2016, 73, 349-363.	2.4	23
147	De Novo and Rare Variants at Multiple Loci Support the Oligogenic Origins of Atrioventricular Septal Heart Defects. PLoS Genetics, 2016, 12, e1005963.	1.5	92
148	Establishing disease causality for a novel gene variant in familial dilated cardiomyopathy using a functional in-vitro assay of regulated thin filaments and human cardiac myosin. BMC Medical Genetics, 2015, 16, 97.	2.1	4
149	Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. PLoS Genetics, 2015, 11, e1005496.	1.5	23
150	Promise of Precision Medicineâ€"Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1752.	3.8	0
151	Systems Genomics Identifies a Key Role forÂHypocretin/Orexin Receptor-2 in Human Heart Failure. Journal of the American College of Cardiology, 2015, 66, 2522-2533.	1.2	31
152	Using â€œBig Dataâ€•to Dissect Clinical Heterogeneity. Circulation, 2015, 131, 232-233.	1.6	28
153	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 570-572.	1.2	5
154	Prevalence and Prognostic Role of Right Ventricular Involvement in Stress-Induced Cardiomyopathy. Journal of Cardiac Failure, 2015, 21, 419-425.	0.7	22
155	Computerized Q wave dimensions in athletes and hypertrophic cardiomyopathy patients. Journal of Electrocardiology, 2015, 48, 362-367.	0.4	16
156	Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy. Journal of Cardiology, 2015, 66, 57-62.	0.8	30
157	Additive prognostic value of a cardiopulmonary exercise test score in patients with heart failure and intermediate risk. International Journal of Cardiology, 2015, 178, 262-264.	0.8	14
158	Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Cardiovascular Genetics, 2015, 8, 421-424.	5.1	6
159	The Precision Medicine Initiative. JAMA - Journal of the American Medical Association, 2015, 313, 2119.	3.8	427
160	Cardiopulmonary Responses and Prognosis in Hypertrophic Cardiomyopathy. JACC: Heart Failure, 2015, 3, 408-418.	1.9	72
161	A Rapid, High-Quality, Cost-Effective, Comprehensive and Expandable Targeted Next-Generation Sequencing Assay for Inherited Heart Diseases. Circulation Research, 2015, 117, 603-611.	2.0	34
162	The Undiagnosed Diseases Network of the National Institutes of Health. JAMA - Journal of the American Medical Association, 2015, 314, 1797.	3.8	97

#	Article	IF	Citations
163	Achieving high-sensitivity for clinical applications using augmented exome sequencing. Genome Medicine, 2015, 7, 71.	3.6	46
164	Gender Differences in Ventricular Remodeling andÂFunction in College Athletes, Insights from Lean Body Mass Scaling and Deformation Imaging. American Journal of Cardiology, 2015, 116, 1610-1616.	0.7	30
165	RNA-Seq identifies novel myocardial gene expression signatures of heart failure. Genomics, 2015, 105, 83-89.	1.3	220
166	Personalized Preventive Medicine: Genetics and the Response to Regular Exercise in Preventive Interventions. Progress in Cardiovascular Diseases, 2015, 57, 337-346.	1.6	57
167	Abstract 16484: The Transcriptional Repressor NR1D2 is Associated With Congenital Heart Disease and Plays an Evolutionarily Conserved Role in Cardiac Development. Circulation, 2015, 132, .	1.6	1
168	Identification of a New Target of miR-16, Vacuolar Protein Sorting 4a. PLoS ONE, 2014, 9, e101509.	1.1	10
169	A Balanced Look at the Implications of Genomic (and Other â€œOmicsâ€) Testing for Disease Diagnosis and Clinical Care. Genes, 2014, 5, 748-766.	1.0	9
170	Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. Journal of Clinical Investigation, 2014, 124, 5159-5174.	3.9	38
171	How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience. BMJ Open, 2014, 4, e004814-e004814.	0.8	14
172	Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations. Journal of the American College of Cardiology, 2014, 64, 2589-2600.	1.2	118
173	Patterns and prognosis of all components of the J-wave pattern in multiethnic athletes and ambulatory patients. American Heart Journal, 2014, 167, 259-266.	1.2	38
174	Latent Obstruction and Left Atrial Size Are Predictors of Clinical Deterioration Leading to Septal Reduction in Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2014, 20, 236-243.	0.7	12
175	Prevalence and Clinical Correlates of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2014, 113, 361-367.	0.7	48
176	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	3.8	398
177	A neural network approach to predicting outcomes in heart failure using cardiopulmonary exercise testing. International Journal of Cardiology, 2014, 171, 265-269.	0.8	39
178	Molecular diagnosis of long QT syndrome at 10 days of life by rapid whole genome sequencing. Heart Rhythm, 2014, 11, 1707-1713.	0.3	48
179	A long noncoding RNA protects the heart from pathological hypertrophy. Nature, 2014, 514, 102-106.	13.7	672
180	Abstract 15528: Myocardial Deformation Imaging and Obstruction in Hypertrophic Cardiomyopathy, Insights from Cross-sectional and Post-myectomy Analysis. Circulation, 2014, 130, .	1.6	0

#	Article	IF	Citations
181	Abstract 12075: Whole-Genome Sequencing at 10-Days of Life in Perinatal Long-QT Syndrome Yields New Insights Into Disease Pathogenesis. Circulation, 2014, 130, .	1.6	0
182	Cardiopulmonary and Noninvasive Hemodynamic Responses to Exercise Predict Outcomes in Heart Failure. Journal of Cardiac Failure, 2013, 19, 101-107.	0.7	22
183	Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. Cell Stem Cell, 2013, 12, 101-113.	5.2	584
184	Effects of Respiratory Exchange Ratio on the Prognostic Value of Peak Oxygen Consumption and Ventilatory Efficiency in Patients With Systolic Heart Failure. JACC: Heart Failure, 2013, 1, 427-432.	1.9	52
185	A Clinical Approach to Inherited Hypertrophy. Circulation: Cardiovascular Genetics, 2013, 6, 118-131.	5.1	22
186	Taming Rare Variation With Known Biology in Long QT Syndrome. Circulation: Cardiovascular Genetics, 2013, 6, 227-229.	5.1	1
187	A public resource facilitating clinical use of genomes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11920-11927.	3.3	194
188	Cardiac Structural and Sarcomere Genes Associated With Cardiomyopathy Exhibit Marked Intolerance of Genetic Variation. Circulation: Cardiovascular Genetics, 2012, 5, 602-610.	5.1	59
189	APJ acts as a dual receptor in cardiac hypertrophy. Nature, 2012, 488, 394-398.	13.7	204
190	Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. Cell, 2012, 148, 1293-1307.	13.5	1,134
191	Cell-Intrinsic Functional Effects of the Î±-Cardiac Myosin Arg-403-Gln Mutation in Familial Hypertrophic Cardiomyopathy. Biophysical Journal, 2012, 102, 2782-2790.	0.2	18
192	Performance comparison of whole-genome sequencing platforms. Nature Biotechnology, 2012, 30, 78-82.	9.4	281
193	Personalized medicine: hope or hype?. European Heart Journal, 2012, 33, 1564-1570.	1.0	59
194	Randomized Trial of Personal Genomics for Preventive Cardiology. Circulation: Cardiovascular Genetics, 2012, 5, 368-376.	5.1	28
195	Systems-Based Approaches to Cardiovascular Biomarker Discovery. Circulation: Cardiovascular Genetics, 2012, 5, 360-367.	5.1	32
196	Genetics and Cardiovascular Disease. Circulation, 2012, 126, 142-157.	1.6	74
197	Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy. Science Translational Medicine, 2012, 4, 130ra47.	5.8	590
198	DNA Sequencing. Circulation, 2012, 125, 931-944.	1.6	72

#	Article	IF	Citations
199	Apelin Enhances Directed Cardiac Differentiation of Mouse and Human Embryonic Stem Cells. PLoS ONE, 2012, 7, e38328.	1.1	36
200	Genetic Analysis in Cardiovascular Disease. Cardiology in Review, 2011, 19, 81-89.	0.6	13
201	Systems biology of heart failure, challenges and hopes. Current Opinion in Cardiology, 2011, 26, 314-321.	0.8	14
202	Personalized Medicine and Cardiovascular Disease: From Genome to Bedside. Current Cardiovascular Risk Reports, 2011, 5, 542-551.	0.8	1
203	Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence. PLoS Genetics, 2011, 7, e1002280.	1.5	137
204	Gene Coexpression Network Topology of Cardiac Development, Hypertrophy, and Failure. Circulation: Cardiovascular Genetics, 2011, 4, 26-35.	5.1	88
205	Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks. Journal of Cardiovascular Translational Research, 2010, 3, 438-447.	1.1	59
206	Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature, 2010, 466, 62-67.	13.7	426
207	Clinical assessment incorporating a personal genome. Lancet, The, 2010, 375, 1525-1535.	6.3	637
208	Challenges in the clinical application of whole-genome sequencing. Lancet, The, 2010, 375, 1749-1751.	6.3	207
209	Aldehyde dehydrogenase activator attenuates diabetic cardiomyopathy; a role in improving the quality of resident cardiac stem cells?. FASEB Journal, 2010, 24, 572.3.	0.2	4
210	Endogenous regulation of cardiovascular function by apelin-APJ. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1904-H1913.	1.5	169
211	Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H1329-H1335.	1.5	136
212	A New Era in Clinical Genetic Testing for Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 381-391.	1.1	25
213	Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy. American Heart Journal, 2009, 158, e27-e34.	1.2	32
214	Pharmacogenetics of Heart Failure: Evidence, Opportunities, and Challenges for Cardiovascular Pharmacogenomics. Journal of Cardiovascular Translational Research, 2008, 1, 25-36.	1.1	3
215	Genetics of Arrhythmia: Disease Pathways Beyond Ion Channels. Journal of Cardiovascular Translational Research, 2008, 1, 155-165.	1.1	4
216	Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. Journal of Clinical Investigation, 2008, 118, 3343-54.	3.9	253

#	Article	IF	Citations
217	Emerging role of the apelin system in cardiovascular homeostasis. Biomarkers in Medicine, 2007, 1, 37-43.	0.6	5
218	Frontiers in Nephrology. Journal of the American Society of Nephrology: JASN, 2007, 18, 2853-2862.	3.0	3
219	Perioperative cardiac risk: pathophysiology, assessment and management. Expert Review of Cardiovascular Therapy, 2006, 4, 731-743.	0.6	2
220	Angiotensin-Converting Enzyme Genotype Predicts Cardiac and Autonomic Responses to Prolonged Exercise. Journal of the American College of Cardiology, 2006, 48, 523-531.	1.2	41
221	Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. European Journal of Heart Failure, 2006, 8, 355-360.	2.9	174
222	Network Analysis of Human In-Stent Restenosis. Circulation, 2006, 114, 2644-2654.	1.6	66
223	Pathway analysis of coronary atherosclerosis. Physiological Genomics, 2005, 23, 103-118.	1.0	144
224	The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovascular Research, 2005, 65, 73-82.	1.8	298
225	Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiological Genomics, 2005, 22, 213-226.	1.0	73
226	Preoperative Cardiac Evaluation: Mechanisms, Assessment, and Reduction of Risk. Thoracic Surgery Clinics, 2005, 15, 263-275.	0.4	11
227	Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction. Circulation, 2003, 108, 1432-1439.	1.6	311
228	Cardiac Nitric Oxide Synthase 1 Regulates Basal and Î²-Adrenergic Contractility in Murine Ventricular Myocytes. Circulation, 2002, 105, 3011-3016.	1.6	155
229	Exercise testing scores as an example of better decisions through science. Medicine and Science in Sports and Exercise, 2002, 34, 1391-1398.	0.2	19
230	Diagnosing coronary artery disease in diabetic patients. Diabetes/Metabolism Research and Reviews, 2002, 18, 201-208.	1.7	14
231	Exercise testing in clinical medicine. Lancet, The, 2000, 356, 1592-1597.	6.3	145
232	Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. Circulation Genomic and Precision Medicine, 0, , .	1.6	0